EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial

Vikas Ostwal iD, Manali Parulekar, Deepali Naughane, Anant Ramaswamy iD, Tejashree Garkal, George John iD, Sarika Mandavkar, Prabhat Bhargava iD, Anuj Gupta iD, Akhil Kapoor iD, Pradnya Joshi, Omshree Shetty iD und 14 weitere

JCO Global Oncology · 2026-03 · 12 (3)

DOI: 10.1200/go-25-00386 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JCO Global Oncology, 2026-03. Verfasst von Vikas Ostwal und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. Hauptthemen laut MEDLINE: Thrombocytopenia, Carica, Plant Extracts, Plant Leaves. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Carica papaya leaf extract (CPLE) is known to increase platelet counts (PCs) in certain infections. METHODS Patients were randomly assigned in a 2:1 ratio to the CPLE or placebo arm and continued treatment until the PC improved to 75,000 × 10 9 /L or above, a platelet transfusion was required, or upto D+10. The primary outcome was to evaluate whether CPLE improves PC faster compared with placebo in a significant proportion of patients with a modified intention-to-treat protocol. RESULTS Between March 2020 and October 2024, 219 patients were randomly assigned, of whom 198 patients (CPLE arm: 129; placebo arm: 69) were analyzed for outcomes. The primary end point with modified intention-to-treat analysis showed a statistically significant increase in PC to ≥75,000 × 10 9 /L in a greater proportion of patients by D+4 compared with placebo (59% v 44%; P = .042). The primary outcome of increasing PC >75,000 × 10 9 /L at D+4 was significantly improved by CPLE (83/129, 64% v 33/69, 48%; P = .034) compared with placebo as per protocol analysis. There was no grade 3 or grade 4 treatment-related adverse events associated with CPLE. About 43% of patients in the placebo arm versus 25% of patients in the CPLE arm needed dose reductions or delays in their subsequent chemotherapy treatment for patients with grade 2 chemotherapy-induced thrombocytopenia (CIT) at the baseline ( P 0.033) and not significant in grade 3 CIT. CONCLUSION CPLE is a potential therapeutic intervention to improve CIT faster and to a greater extent than placebo in this phase III randomized trial without any safety concerns. It could be potentially used as a secondary prophylaxis to maintain the chemotherapy intensity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaCaricaPlant ExtractsPlant LeavesAntineoplastic AgentsHumansFemaleMiddle AgedMalePlatelet CountAgedAdultDouble-Blind Method

Substanzen

Plant ExtractsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India.
  • Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Medical Oncology, Bharat Cancer Centre, Kottayam, India.
  • Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India.

ORCID-Profile: Vikas Ostwal, Anant Ramaswamy, George John, Prabhat Bhargava, Anuj Gupta, Akhil Kapoor, Omshree Shetty, Sujay Srinivas, Sadhana Kannan, Amit Joshi, Jaya Ghosh, Vanita Noronha, Nandini Menon, Kumar Prabhash, Shripad Banavali, Sudeep Gupta

Zitieren

APA

Ostwal, V., Parulekar, M., Naughane, D., Ramaswamy, A., Garkal, T., John, G., Mandavkar, S., Bhargava, P., Gupta, A., Kapoor, A., Joshi, P., Shetty, O., Srinivas, S., Kannan, S., Chaugule, D., Jadhav, P., Joshi, A., Ghosh, J., Noronha, V., …, & Gupta, S. (2026). Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial. JCO Global Oncology, 12(3). https://doi.org/10.1200/go-25-00386

Vancouver

Ostwal V, Parulekar M, Naughane D, Ramaswamy A, Garkal T, John G, et al. Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial. JCO Global Oncology. 2026;12(3). doi:10.1200/go-25-00386

BibTeX
@article{Ostwal2026,
  author = {Ostwal, Vikas and Parulekar, Manali and Naughane, Deepali and Ramaswamy, Anant and Garkal, Tejashree and John, George and Mandavkar, Sarika and Bhargava, Prabhat and Gupta, Anuj and Kapoor, Akhil and Joshi, Pradnya and Shetty, Omshree and Srinivas, Sujay and Kannan, Sadhana and Chaugule, Deepali and Jadhav, Poonam and Joshi, Amit and Ghosh, Jaya and Noronha, Vanita and Menon, Nandini and Prabhash, Kumar and Khandare, Mahesh and More, Sucheta and Gaud, Supriya and Banavali, Shripad and Gupta, Sudeep},
  title = {Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1200/go-25-00386}
}
Kostenlos starten →